Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 17, 2026
Reporting period
Not applicable
Filed with the SEC
Aug 19, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002021238-26-000012
Filed / recorded
Aug 19, 2026, 10:35 PM UTC
Added to OQRO
Oct 7, 2026, 6:56 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
MapLight Therapeutics, Inc.
Issuer CIK
1770069
Ticker
MPLT
Reporting person
Anatol Kreitzer
Relationship
Officer
Officer title
Chief Discovery Officer
Security
Employee Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Aug 17, 2026
Transaction code
A
Shares / units
24,455
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
24,455
Ownership form
Direct
Amendment
No
Footnotes from the filing
1/4th of the total shares underlying the option shall vest on July 1, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.